Larimar Therapeutics (LRMR) said Monday that initial data from its ongoing long-term study of its experimental therapy nomlabofusp in patients with Friedreich's ataxia leaned toward improved clinical outcomes at day 90.
The company said patients treated with daily injections of nomlabofusp saw tissue frataxin levels increase, supporting the drug's potential in treating Friedreich's ataxia.
Larimar said dose escalation has started in six participants, and screening for adolescents with Friedreich's ataxia is ongoing, with dosing expected in early 2025.
The company said it plans to begin a global confirmatory study in mid-2025 and submit a biologics license application in H2 2025 for potential accelerated approval.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。